Wolverine Blend

The Wolverine Blend combines BPC-157, derived from a gastric protective protein, and TB-500 (thymosin beta-4), two research peptides known for complementary roles in tissue repair and recovery. BPC-157 has been studied for its potential to support tendon, ligament, muscle, and gastrointestinal tissue repair. TB-500 is researched for cell migration, angiogenesis, and tissue regeneration. The blend is commonly used in research settings for recovery from acute injuries, chronic overuse conditions, and post-procedure healing.

• Tendon and ligament repair
• Muscle recovery
• Joint health
• Inflammatory response
• Gastrointestinal health
• Post-procedure recovery
• Overall tissue repair and recovery

• BPC-157 may support localized repair processes in tendons, ligaments, muscles, and gut tissue
• TB-500 may support cell migration, angiogenesis, and tissue regeneration
• Together, the blend may enhance natural healing mechanisms, reduce inflammation, and support faster recovery
• The combination is frequently researched for synergistic effects in tissue repair and recovery

10 mg + 10 mg reconstitution

1 mL bacteriostatic water

10 mg + 10 mg starting dose

0.5 mg + 0.5 mg (5 units)

10 mg + 10 mg typical range

0.5 mg to 2 mg each

30 mg + 30 mg reconstitution

3 mL bacteriostatic water

30 mg + 30 mg starting dose

0.5 mg + 0.5 mg (5 units)

30 mg + 30 mg typical range

0.5 mg to 2 mg each

Frequency

Daily

Cycle duration

8–12 weeks

Notes

Acute injury research: 1–2 mg each daily. Maintenance: 0.5–1 mg each, 3–5 times per week, as listed on the sheet.

Research duration on the sheet: 8–12 weeks on the source sheet.

• 10 mg + 10 mg: add 1 mL bacteriostatic water (10 mg/mL each). 5 units = 0.5 mg + 0.5 mg. 10 units = 1 mg + 1 mg.
• 30 mg + 30 mg: add 3 mL bacteriostatic water (10 mg/mL each). 5 units = 0.5 mg + 0.5 mg. 10 units = 1 mg + 1 mg.

• The sheet lists a range of 0.5–2 mg of each component rather than a fixed weekly escalation.
• Acute-injury research is listed toward 1–2 mg each daily. Maintenance is listed at 0.5–1 mg each, 3–5 times per week.

• Not approved for human use. BPC-157 is prohibited by WADA.
• Not for use in pregnancy or breastfeeding.
• Avoid use in active or recent cancer research unless under medical supervision.
• Possible side effects include mild injection-site irritation, nausea, or headaches.
• Long-term safety has not been established.

• The sheet notes possible mild injection-site irritation, nausea, or headaches.

Position on the sheet

Research and educational purposes only

Completed published studies are listed below and labeled as in vitro, animal, or human research. Favorable and unfavorable results are both included, including cancer studies. This is not every paper on the compound, and it is not a recommendation or a dose.

No completed study of this blend as one product was identified. The links are completed studies of peptides in the blend.

• BPC 157 accelerates healing of a transected rat Achilles tendonAnimal

  Rats with a cut Achilles tendon recovered more function, strength, and collagen organization than saline controls.

• BPC 157 as therapy for a transected quadriceps muscle in the ratAnimal

  Rats. A fully cut quadriceps regained more strength, walking function, and muscle continuity over 72 days.

• BPC 157 increases new-vessel growth through VEGFR2In vitro

  Human endothelial cells formed more vessel-like tubes, and rats grew more vessels in an ischemic limb. The study did not implant a tumor. New-vessel growth is the result cancer researchers watch.

• BPC 157 in mice with colon-cancer cachexiaAnimal

  Mice with C26 colon tumors. The report describes better body weight, less muscle wasting, and lower IL-6 and TNF-alpha. Tumor volume was lower on average, and that difference was not statistically significant.

• Thymosin beta-4 accelerates wound healingAnimal

  Rats. Full-thickness skin wounds closed faster, with more collagen and new blood vessels, after thymosin beta-4.

• Thymosin beta-4 in human pancreatic cancer cellsIn vitro

  Pancreatic cancer cells made more thymosin beta-4 than normal duct cells. Adding the peptide increased inflammatory signals associated with tumor support.

• Thymosin beta-4 overexpression makes colon cancer cells harder to killIn vitro

  Colon cancer cells forced to make extra thymosin beta-4 resisted cell death from immune-cell signals and from two chemotherapy drugs.

10 mg + 10 mg, or 30 mg + 30 mg. Format: Lyophilized powder.